[Efficacy of Fecal Microbial Transplantation for Improving Symptoms of Irritable Bowel Syndrome - A Pilot Study for Voluntary Participants in Korea].

Jung Won Lee, Nayoung Kim
{"title":"[Efficacy of Fecal Microbial Transplantation for Improving Symptoms of Irritable Bowel Syndrome - A Pilot Study for Voluntary Participants in Korea].","authors":"Jung Won Lee, Nayoung Kim","doi":"10.4166/kjg.2024.107","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/aims: </strong>Irritable bowel syndrome (IBS) is a chronic, intractable functional disease. It is inferred that fecal microbiota transplantation (FMT) may have favorable efficacy on IBS by gut microbial modification. The aim of this study was to investigate the efficacy of FMT for improving severity in patients with IBS.</p><p><strong>Methods: </strong>Patients who voluntarily wanted FMT were consecutively enrolled. The study subjects were classified by subtype of IBS by the ROME IV criteria. The IBS-symptom severity score (IBS-SSS) was used to evaluate the efficacy of FMT. The subjects completed a questionnaire at baseline week 0 and weeks 4, 12, and 24 after FMT. FMT was performed by esophagogastroduodenoscopy using frozen stock stool solution. If the follow-up IBS-SSS achieved less than 75 points, it was defined as remission. Adverse events were also gathered.</p><p><strong>Results: </strong>Twenty-one subjects were included from October 2023 until July 2024. There were 7 patients with IBS-C, 10 patients with IBS-D, 2 patients with IBS-M, and 2 patients with IBS-U type. The mean SSS of the IBS-D group was 244.0±64.2, which was higher than IBS-C group (192.9±85.4). Alleviations in IBS-SSS after FMT were observed in 19 subjects (19/21, 90.5%) at week 4. At week 12, 71.4% (5/7) in the IBS-C group and 20.0% (2/10) in the IBS-D group achieved remission. The remission states were maintained up to week 24 and no serious adverse events were reported.</p><p><strong>Conclusions: </strong>FMT might be an effective treatment option for improving symptoms of mild to moderate IBS, especially IBS-C.</p>","PeriodicalId":94245,"journal":{"name":"The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4166/kjg.2024.107","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background/aims: Irritable bowel syndrome (IBS) is a chronic, intractable functional disease. It is inferred that fecal microbiota transplantation (FMT) may have favorable efficacy on IBS by gut microbial modification. The aim of this study was to investigate the efficacy of FMT for improving severity in patients with IBS.

Methods: Patients who voluntarily wanted FMT were consecutively enrolled. The study subjects were classified by subtype of IBS by the ROME IV criteria. The IBS-symptom severity score (IBS-SSS) was used to evaluate the efficacy of FMT. The subjects completed a questionnaire at baseline week 0 and weeks 4, 12, and 24 after FMT. FMT was performed by esophagogastroduodenoscopy using frozen stock stool solution. If the follow-up IBS-SSS achieved less than 75 points, it was defined as remission. Adverse events were also gathered.

Results: Twenty-one subjects were included from October 2023 until July 2024. There were 7 patients with IBS-C, 10 patients with IBS-D, 2 patients with IBS-M, and 2 patients with IBS-U type. The mean SSS of the IBS-D group was 244.0±64.2, which was higher than IBS-C group (192.9±85.4). Alleviations in IBS-SSS after FMT were observed in 19 subjects (19/21, 90.5%) at week 4. At week 12, 71.4% (5/7) in the IBS-C group and 20.0% (2/10) in the IBS-D group achieved remission. The remission states were maintained up to week 24 and no serious adverse events were reported.

Conclusions: FMT might be an effective treatment option for improving symptoms of mild to moderate IBS, especially IBS-C.

[粪便微生物移植对改善肠易激综合征症状的疗效--针对韩国自愿参与者的试点研究]。
背景/目的:肠易激综合征(IBS)是一种慢性、难治的功能性疾病。据推断,粪便微生物群移植(FMT)可通过改变肠道微生物对肠易激综合征产生良好疗效。本研究旨在探讨粪便微生物群移植对改善肠易激综合征患者病情严重程度的疗效:方法:连续招募自愿接受 FMT 的患者。研究对象根据 ROME IV 标准按 IBS 亚型分类。肠易激综合征症状严重程度评分(IBS-SSS)用于评估 FMT 的疗效。受试者在 FMT 后第 0 周、第 4 周、第 12 周和第 24 周填写问卷。FMT 通过食管胃十二指肠镜使用冷冻粪便溶液进行。如果随访的 IBS-SSS 评分低于 75 分,则被定义为缓解。此外,还收集了不良事件:从 2023 年 10 月到 2024 年 7 月,共纳入 21 名受试者。其中有 7 名 IBS-C 型患者、10 名 IBS-D 型患者、2 名 IBS-M 型患者和 2 名 IBS-U 型患者。IBS-D 组的平均 SSS 为 244.0±64.2,高于 IBS-C 组(192.9±85.4)。第 4 周时,19 名受试者(19/21,90.5%)的 IBS-SSS 在 FMT 治疗后得到缓解。第 12 周时,IBS-C 组中有 71.4%(5/7)和 IBS-D 组中有 20.0%(2/10)的患者病情得到缓解。缓解状态一直维持到第24周,且无严重不良反应报告:结论:FMT 可能是改善轻度至中度肠易激综合征(尤其是肠易激综合征-C)症状的有效治疗方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信